Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Tuberc Other Mycobact Dis ; 16: 100106, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31720430

ABSTRACT

BACKGROUND: In patients with suspected pulmonary tuberculosis, who have difficulty in expectorating sputum, alternative specimens by invasive procedures, gastric aspirate or sputum suction, are not always available in the feeble elderly. Several studies report the benefit of stool test for pediatric or HIV infected patients, but few in adult patients. OBJECTIVE: To evaluate the benefit of stool examination as non-invasive alternative test to detect Mycobacterium tuberculosis (MTB) infection. METHODS: Stool specimens were examined for mycobacteria in 187 cases of microbiologically-diagnosed pulmonary tuberculosis between September 2013 and August 2017. We retrospectively reviewed the medical records to determine the positive detection rate of MTB with stool specimens and investigated factors related to MTB detection. RESULTS: Among 187 patients included, positive rate of MTB in stool was 12.8% (24/187) by stool acid-fast bacilli smear, 68.1% (98/144) by TRC Rapid®, and 40.6% (76/187) by culture. Multivariate logistic regression analysis revealed two contributing factors to MTB detection in stool; cavitation and male. The adjusted odds ratio with 95% confidence interval (CI) for cavitation was 2.9 (95%CI 1.48-5.69) and 2.1 (95%CI 1.08-3.93) for male. CONCLUSION: We recommend stool examination for those who are unable to give sputum and have risks for invasive procedures.

2.
Mol Microbiol ; 106(2): 207-222, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28792090

ABSTRACT

Quinone-based compounds have been exploited to treat infectious diseases and cancer, with such chemicals often functioning as inhibitors of key metabolic pathways or as prodrugs. Here, we screened an aziridinyl 1,4-benzoquinone (ABQ) library against the causative agents of trypanosomiasis, and cutaneous leishmaniasis, identifying several potent structures that exhibited EC50 values of <100 nM. However, these compounds also displayed significant toxicity towards mammalian cells indicating that they are not suitable therapies for systemic infections. Using anti-T. brucei ABQs as chemical probes, we demonstrated that these exhibit different trypanocidal modes of action. Many functioned as type I nitroreductase (TbNTR) or cytochrome P450 reductase (TbCPR) dependent prodrugs that, following activation, generate metabolites which promote DNA damage, specifically interstrand crosslinks (ICLs). Trypanosomes lacking TbSNM1, a nuclease that specifically repairs ICLs, are hypersensitive to most ABQ prodrugs, a phenotype exacerbated in cells also engineered to express elevated levels of TbNTR or TbCPR. In contrast, ABQs that contain substituent groups on the biologically active aziridine do not function as TbNTR or TbCPR-activated prodrugs and do not promote DNA damage. By unravelling how ABQs mediate their activities, features that facilitate the desired anti-parasitic growth inhibitory effects could be incorporated into new, safer compounds targeting these neglected tropical diseases.


Subject(s)
Benzoquinones/metabolism , Nitroreductases/metabolism , Trypanocidal Agents/pharmacology , Animals , Aziridines/metabolism , Benzoquinones/pharmacology , DNA/metabolism , DNA Damage/drug effects , Humans , NADPH-Ferrihemoprotein Reductase/metabolism , Prodrugs , Structure-Activity Relationship , Trypanosoma brucei brucei/drug effects , Trypanosoma brucei brucei/metabolism , Trypanosoma cruzi/metabolism
4.
Int J Clin Oncol ; 18(1): 96-104, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22095245

ABSTRACT

BACKGROUND: Ethnic differences in drug susceptibility and toxicity are a major concern, not only in drug development but also in the clinical setting. We review the toxicity profiles of docetaxel according to dose and ethnicity. METHODS: We analyzed phase II and III clinical trials that included a once-every-3-weeks single-agent docetaxel arm. Logistic regression analysis was applied to identify the significant variables affecting the reported incidence of docetaxel-induced severe neutropenia. RESULTS: Multivariate logistic regression analysis identified studies conducted in Asia [odds ratio (OR) 19.0; 95% confidence interval (95% CI) 3.64-99.0] and docetaxel dose (OR 1.08; 95% CI 1.03-1.13) as independent variables for the incidence of grade 3/4 neutropenia. CONCLUSIONS: There is a significant difference in the incidence of docetaxel-induced severe neutropenia between Asian and non-Asian clinical studies. Physicians and pharmacists should consider ethnic diversity in docetaxel toxicity when interpreting the results of clinical trials.


Subject(s)
Neoplasms/complications , Neoplasms/epidemiology , Neutropenia/pathology , Taxoids/adverse effects , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Docetaxel , Dose-Response Relationship, Drug , Ethnicity/genetics , Humans , Neoplasms/drug therapy , Neutropenia/chemically induced , Neutropenia/epidemiology , Taxoids/administration & dosage , Taxoids/pharmacokinetics
5.
Eur J Nucl Med Mol Imaging ; 31(3): 388-98, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14647982

ABSTRACT

In spite of recent advances in bone cellular and molecular biology, there is still a poor correlation between these parameters and data obtained from bone scintigraphy. Diphosphonate derivatives radiolabelled with technetium-99m (Tc-BPs) have long been recognised as bone-seeking agents with an affinity for areas of active mineralisation. However, during clinical trials with a pH-sensitive tumour agent, the pentavalent technetium complex of dimercaptosuccinic acid [Tc(V)-DMS] showed a noticeable osteotropic character only in bone pathologies (bone metastases, Paget's diseases) and lacked accumulation in normal mature bone. To decipher the osteotropic character of Tc(V)-DMS, a study at the cellular level was considered necessary. Moreover, to learn more about the role of Tc bone agents, acid-base regulation by bone tissue or cells was studied. First, biological parameters in body fluid were measured under systemic acidosis, induced by glucose administration, in normal and Ehrlich ascites tumour (EAT)-bearing mice. Then, in vivo biodistribution studies using Tc(V)-DMS or a conventional Tc-BP agent were carried out. The effect of glucose-mediated acidification on the skeletal distribution of the Tc agents in the mice provided valuable hints regarding the differential mediation of bone cells in skeletal tissue affinity for the agents. Thereafter, in vitro studies on osteoblast and osteoclast cells were performed and the comparative affinity of Tc(V)-DMS and Tc-BP was screened under diverse acidification conditions. Moreover, studies were also carried out on acid-base parameters related to the cellular uptake mechanism. Very specific pH-sensitive Tc(V)-DMS accumulation only in the osteoclastic system was detected, and use of Tc(V)-DMS in the differential detection of osteoblastic and osteoclastic metastases is discussed.


Subject(s)
Bone and Bones/diagnostic imaging , Bone and Bones/metabolism , Osteoblasts/diagnostic imaging , Osteoblasts/metabolism , Technetium Tc 99m Dimercaptosuccinic Acid/pharmacokinetics , Acidosis/diagnostic imaging , Acidosis/metabolism , Aging/metabolism , Animals , Animals, Newborn , Bone and Bones/chemistry , Carcinoma, Ehrlich Tumor/diagnostic imaging , Carcinoma, Ehrlich Tumor/metabolism , Cell Line, Tumor , Hydrogen-Ion Concentration , Male , Metabolic Clearance Rate , Mice , Mice, Inbred Strains , Organ Specificity , Osteoblasts/chemistry , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...